Meningioma symptoms can include headaches, vision changes, seizures, and cognitive effects. If you used Depo-Provera and have been diagnosed with or are being evaluated for a meningioma, you may have legal options.
If you've used Depo-Provera and are experiencing neurological symptoms, you may be wondering whether they could be related to a meningioma, a type of brain tumor that has been linked to long-term Depo-Provera use. Understanding the symptoms of meningioma after Depo-Provera use can help you recognize potential warning signs and determine whether you should seek medical evaluation.
Recent research has revealed a connection between long-term Depo-Provera use and the development of meningiomas, tumors that form on the protective layers surrounding the brain and spinal cord. A landmark French study found that women who used high-dose progestogen medications like Depo-Provera for extended periods faced significantly elevated risks of developing these tumors. Recognizing the symptoms early can be important for timely diagnosis and treatment.
Pharmaceutical products and medical research documents
What Are Meningiomas?
Meningiomas are tumors that form on the meninges, the protective layers surrounding the brain and spinal cord. While typically non-cancerous, they can cause serious symptoms as they grow. These tumors develop from cells in the meninges and can vary in size and location, which affects both symptoms and treatment options.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Meningiomas are the most common type of primary brain tumor, accounting for approximately one-third of all brain tumors. While most are benign, they can still cause serious health issues depending on their location and size. Treatment options may include monitoring, surgery, radiation therapy, or a combination of approaches depending on the individual case.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The connection between Depo-Provera and meningiomas emerged from comprehensive research examining the medical records of thousands of women. The study found that women who used Depo-Provera for extended periods, particularly five or more years, faced substantially higher risks of developing meningiomas compared to women who did not use the medication.
Common Symptoms of Meningioma
The symptoms of meningioma can vary widely depending on the size and location of the tumor. Some meningiomas may cause no symptoms and are discovered incidentally during imaging for other conditions, while others can lead to significant neurological problems requiring immediate treatment.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Headaches: Persistent headaches are one of the most common symptoms of meningioma. These headaches may be different from typical headaches and may worsen over time or be more severe in the morning. They may not respond well to typical headache medications and may be accompanied by other neurological symptoms.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Vision Problems: Meningiomas located near the optic nerves or visual pathways can cause vision problems. These may include blurred vision, double vision, loss of peripheral vision, or complete vision loss in one or both eyes. Vision changes may develop gradually or appear suddenly depending on the tumor's location and growth rate.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Hearing Loss or Ringing: Meningiomas located near the auditory nerves can cause hearing loss, ringing in the ears (tinnitus), or a feeling of fullness in the ears. These symptoms may affect one or both ears and may develop gradually over time.
According to CDC National Health Statistics Reports, injectable contraceptives are used by roughly 2% to 3% of U.S. women aged 15–49 who use contraception—a smaller share than oral methods but clinically significant at population scale.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Memory Difficulties: Meningiomas can affect cognitive function, leading to memory problems, difficulty concentrating, or changes in thinking abilities. These symptoms may be subtle at first and may be mistaken for normal aging or stress-related issues.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Seizures: Some meningiomas can cause seizures, which may be the first sign of the tumor. Seizures can vary in type and severity, from brief staring spells to full convulsive seizures. Any new seizure activity should be evaluated by a healthcare provider immediately.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Weakness in Limbs: Meningiomas that affect motor pathways can cause weakness, numbness, or tingling in the arms or legs. This may affect one side of the body more than the other and may develop gradually over time.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewPersonality Changes: Some meningiomas can cause personality changes, mood swings, or behavioral changes. These may be subtle and may be noticed by family members or close friends before the individual recognizes them.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
If you've used Depo-Provera for an extended period and are experiencing any of these symptoms, you may want to learn more about Depo-Provera lawsuit information and your potential rights.
Legal documents and research papers representing ongoing litigation
When Symptoms May Appear
The timeline for when meningioma symptoms appear after Depo-Provera use can vary significantly from person to person. Some women may develop symptoms relatively quickly after years of medication use, while others may not experience symptoms until many years later.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Research suggests that the risk of developing meningiomas increases with the duration of Depo-Provera use. Women who used the medication for extended periods, particularly five or more years, may face significantly higher risks. The cumulative nature of the exposure means that symptoms may develop gradually over time as the tumor grows.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
It's important to understand that meningiomas are typically slow-growing tumors, which means symptoms may not appear immediately after exposure begins. The tumors develop gradually, and symptoms may only become noticeable when the tumor reaches a certain size or affects specific areas of the brain. This variability in symptom onset makes it important to monitor your health if you've used Depo-Provera for extended periods.
The Connection Between Depo-Provera and Meningiomas
Recent scientific research has revealed a connection between long-term Depo-Provera use and the development of meningiomas. A landmark French study published in the BMJ found that women who used high-dose progestogen medications like Depo-Provera for extended periods faced significantly elevated risks of developing these tumors.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationAccording to CDC National Health Statistics Reports, injectable contraceptives are used by roughly 2% to 3% of U.S. women aged 15–49 who use contraception—a smaller share than oral methods but clinically significant at population scale.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
The study found that women who used Depo-Provera for extended periods faced substantially higher risks of developing meningiomas compared to women who did not use the medication. The risk increased with the duration of use, indicating that cumulative exposure over time plays a significant role in tumor development.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The research suggests that the hormone medroxyprogesterone acetate, the active ingredient in Depo-Provera, may play a role in the development of these tumors. While the exact mechanism is still being studied, the evidence indicates a clear association between long-term Depo-Provera use and increased meningioma risk. Women who develop symptoms after using the medication should consider having their situation evaluated.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitWhat Is Depo-Provera?
Depo-Provera is an injectable contraceptive medication that contains the hormone medroxyprogesterone acetate. The medication is administered as an injection every three months to prevent pregnancy. It has been used by millions of women worldwide since its approval by the FDA in 1992.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The medication works by preventing ovulation and thickening cervical mucus to block sperm. While effective for birth control, emerging research has raised concerns about potential long-term health risks, particularly related to brain tumor development. Many women have used Depo-Provera for extended periods, sometimes for years or even decades, which may have contributed to the increased risk observed in recent studies.
Depo-Provera injections are typically administered by healthcare providers into the muscle of the arm or buttock. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness for approximately 12 to 14 weeks. The cumulative exposure from repeated injections over many years may be a factor in the increased meningioma risk observed in long-term users.
How Exposure Occurred
Women were exposed to Depo-Provera through regular injections administered by healthcare providers. The medication is typically injected into the muscle of the arm or buttock every 12 to 14 weeks. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Exposure occurred through regular injections every three months, long-term use over multiple years, cumulative exposure building up over time, and direct injection into muscle tissue. Many women used Depo-Provera for extended periods, sometimes for years or even decades. This long-term, repeated exposure may have contributed to the increased risk of developing meningiomas observed in recent studies.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The cumulative nature of the exposure is particularly important when considering symptom development. The hormone builds up in the body over time with each injection, and women who received injections for many years may have had significantly higher cumulative exposure than those who used the medication for shorter periods. This cumulative exposure may explain why symptoms may develop gradually over time.
Evidence and documents in legal proceedings
Who May Be Affected
Women who used Depo-Provera for extended periods may be at increased risk of developing meningiomas and experiencing related symptoms. Research suggests that the risk increases with the duration of use. Women who used the medication for one to four years may face a moderate increase in risk, while those who used it for five or more years may face significantly higher risks. Women who used it for ten or more years may face the highest risks.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk, with some groups facing risks more than five times higher than non-users. Women who have used Depo-Provera for extended periods and are experiencing symptoms that could be related to meningioma should consider having their situation evaluated to determine whether they may have a valid legal claim.
If you've used Depo-Provera for an extended period and are experiencing symptoms that could be related to meningioma, you may want to learn more about Depo-Provera lawsuit information and your potential rights.
Current Status of Litigation
Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis. Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
The litigation is in early stages, with cases being filed in various courts. As more scientific evidence emerges and more women come forward with symptoms and diagnoses, the litigation may develop into consolidated proceedings similar to other pharmaceutical mass tort cases. Scientific evidence continues to accumulate linking progestogen exposure to meningioma development, and this evidence may support legal claims that manufacturers had an obligation to warn about these risks but failed to do so adequately.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Evidence suggests that the risks associated with progestogen exposure were known for years before adequate warnings were provided. Pharmaceutical companies have a legal obligation to warn patients and healthcare providers about known risks. If you've used Depo-Provera for an extended period and developed symptoms or been diagnosed with a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
What a Case Review Involves
A case review is an initial evaluation to determine whether you may have a valid legal claim related to Depo-Provera use and meningioma development. This process is confidential, free, and does not create any obligation on your part.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history, any symptoms you've experienced, and your medical diagnosis if you have one. You'll be asked about when you started using Depo-Provera, how long you used it, when you began experiencing symptoms, when you received your meningioma diagnosis if applicable, and what symptoms you've experienced.
Medical Records Review: If you decide to proceed, medical records related to your symptoms, diagnosis, and treatment may be reviewed. This helps establish the connection between your medication use and your condition. You may also be asked about your Depo-Provera injection history and any documentation you have.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitEligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the symptoms you've experienced, the timing of your diagnosis relative to your medication use, and how your case fits within the broader litigation.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases. If you don't qualify, you'll receive an explanation of why.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
No Upfront Costs: Case reviews are conducted at no cost to you. If you qualify and choose to proceed with a case, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful. To understand more about how mass tort cases work, you may find our guide on understanding mass tort litigation helpful.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
Symptoms warrant care first
Headaches or vision changes require prompt medical evaluation regardless of legal plans. After you are stable, a case review can explore whether symptom onset aligns with typical meningioma litigation theories.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewScientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
Litigation Timeline: Mass tort litigation typically takes several years to resolve. Cases may proceed through discovery, expert witness preparation, and potentially trials or settlement negotiations. The timeline for your specific case depends on many factors beyond your control.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Important Disclaimers
Recognizing the symptoms of meningioma after Depo-Provera use is an important first step in understanding your potential legal rights. If you've used Depo-Provera for an extended period and are experiencing symptoms that could be related to meningioma, or if you've been diagnosed with a meningioma, understanding your legal options is important.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Emotional harm may be compensable when tied to physical injury and treatment. Document mental-health care consistently if those symptoms are part of your story.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
